window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-ZXTT8H6EZ1');

News

News2020-11-24T14:50:45+00:00

News

Project news, updates, and announcements.

3101, 2022

The EUPHORIA consortium plenary meeting, January 2022

January 31st, 2022|

The EUPHORIA partners met on Friday 28 January for an online plenary meeting. The meeting focused on the EUPHORIA study, which is now open at 3 sites (2 in Germany and 1 in Italy), with plans for 2 more sites to open soon (1 in Milan and 1 in Berlin). Recruitment continues despite the challenges presented by COVID-19. As we enter the final 6 months of the project we look forward to the generation of interim study results in the coming weeks. The EUPHORIA team hope to hold our final project meeting in person in May/June 2022.

2212, 2021

The EUPHORIA study features on the DCCV website!

December 22nd, 2021|

Through the European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA),  an umbrella organisation representing 41 national Crohn’s and Ulcerative Colitis (collectively Inflammatory Bowel Disease or IBD) patient associations, we identified the German Crohn’s disease and Ulcerative Colitis Association (DCCV, https://www.dccv.de/die-dccv/), the advocacy organization for more than 400,000 people with chronic inflammatory bowel disease in Germany, as a patients-centred organisation to feature and promote the EUPHORIA clinical study with their cohort.

Contact was established with the DCCV to publicise the EUPHORIA study to the DCCV audience. A feature on the EUPHORIA study was agreed with the DCCV and published on their website, https://www.dccv.de/einzelne-studienaufrufe/euphoria-ultrasound-photoaktustik-mc-052021/

2511, 2021

iThera Medical discusses their business goals in relation to EU-partnerships in new video

November 25th, 2021|

In a new video, iThera Medical CEO Christian Wiest and CCO Philipp Bell discuss their R & D strategy and primary business goals in relation to the EU-funded projects EUPHORIA and STARSTEM (www.starstem.eu, Related Project, grant number 761214). They describe the criteria and key performance indicators they use to forge and evaluate university partnerships: the organizational structures, types of partner organizations and processes that support iThera’s primary business goals.

Special thanks to Christian and Philipp for sharing their thoughts on and vision for success.

 

 

 

 

1410, 2021

Welcome to the EUPHORIA team, Claudia!

October 14th, 2021|

Claudia Jendrewski

One hallmark of success is to see the size of the workforce at iThera Medical growing. One such recent addition has joined the team of researchers on the EUPHORIA project. We welcome Claudia Jendrewski, who joined ITM in October 2021 as a Clinical Trial Manager.

Claudia is leading iThera-sponsored clinical investigations. She holds an MSc. in Medical Engineering from the Technical University of Munich. Before joining iThera, Claudia worked at Brainlab AG for five years coordinating, planning and overseeing clinical studies and validation activities with medical devices.

Welcome, Claudia!

710, 2021

Partner News: iThera Medical introduces the world’s first transmission ultrasound system

October 7th, 2021|

Today, EUPHORIA Coordinators iThera Medical announced the launch of its new inVision TRIO preclinical optoacoustic imaging system. The inVision TRIO is the first imaging system in the world that incorporates transmission ultrasound computed tomography (TUCT) and expands the field of biomedical applications addressable using iThera Medical’s optoacoustic imaging systems.

The new inVision TRIO offers tremendous flexibility for imaging disease processes. The key innovation is the addition of TUCT, which provides an accurate image of the speed of sound in tissue and its change with disease, e.g., in the context of cancer or fibrosis. Through this new development, the inVision TRIO delivers complementary information from three modalities: MSOT, reflection-mode ultrasound CT, and transmission-mode ultrasound CT. Coupled with unique features like a seamless 660-1,300 nm wavelength range and calibrated signal quantification, the inVision TRIO will allow researchers to drive their applications into previously unexplored areas.

Christian Wiest, CEO of iThera Medical, describes the motivation to develop the inVision TRIO system: “With the MSOT inVision on the market since 2012 and our focus in the past years on clinical translation, we felt it was time to update our preclinical system. The original MSOT inVision was the world’s first tomographic optoacoustic imaging system. We are excited that the inVision TRIO will now follow in these footsteps as the world’s first tri-modality optoacoustic imaging system, incorporating TUCT as a breakthrough innovation.”

To learn more about the new inVision TRIO imaging platform, see http://www.ithera-medical.com/products/preclinical-research/invision-trio/

Read the full press […]

2309, 2021

PRESS RELEASE: iThera Medical reports initiation of second site in ongoing clinical study for the non-invasive assessment of inflammatory bowel disease

September 23rd, 2021|

Medical device company iThera Medical announces that the second site in Germany has been initiated for the ongoing clinical study in the EU-funded Horizon 2020 project EUPHORIA. The project aims to further develop the company’s proprietary optoacoustic imaging technology and demonstrate its clinical value in the assessment of inflammatory bowel disease (IBD).

The €2.3 million Horizon 2020 research project EUPHORIA (Enhancing Ultrasound and PHOtoacoustics for Recognition of Intestinal Abnormalities) led by iThera Medical aims to assess the ability of MSOT to measure disease activity in patients with IBD. Clinical validation of the diagnostic performance of the MSOT Acuity Echo investigational device is underway in a multicenter international study, with the Jena University Hospital (JUH) now added as the latest initiated site and the second site in Germany. JUH has already enrolled and successfully scanned the first patients with the MSOT Acuity Echo device. Two additional sites in Italy are slated for initiation in the coming weeks, with the project leaders expecting these sites to open within Q4/2021.

The initiation of new study sites will allow for faster patient recruitment to acquire data necessary for the clinical validation of the MSOT technology in the application of disease monitoring in IBD. Furthermore, iThera Medical will use the feedback from the various patient and investigator groups to guide the ongoing development of the MSOT technology to best benefit doctors and their patients.

We are excited to be part of this groundbreaking clinical […]

Go to Top